Juvenile idiopathic arthritis (JIA) is the term used to describe a group of inflammatory articular disorders of unknown cause that begin before the age of 16 and last over 6 weeks. The term juvenile i...
Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
The limited documentation surrounding juvenile idiopathic arthritis is largely due to its rarity, affecting a small number of children worldwide. This rarity restricts the scope of systematic clinical studies, making it challenging to gather comprehensive data. Additionally, the absence of identified genetic factors and inheritance patterns complicates the understanding of the condition, leading to gaps in clinical characterization.
To navigate juvenile idiopathic arthritis effectively, seek a pediatric rheumatologist who specializes in inflammatory joint disorders. They can provide tailored management strategies and monitor disease progression. You can also explore participation in clinical trials, which may offer access to cutting-edge therapies. For additional resources, visit GARD at rarediseases.info.nih.gov for information on rare diseases. Although no patient organizations are currently identified, connecting with other families through online forums may provide support and shared experiences.
In the realm of treatment, there are currently two FDA-approved medications for JIA: adalimumab and meloxicam. Additionally, several orphan drugs are in development, including Gammalinolenic acid and various other compounds targeting inflammatory pathways. There are 74 active clinical trials exploring new treatments and management strategies for JIA. For more information on these trials, you can visit ClinicalTrials.gov and search for juvenile idiopathic arthritis.
Actionable guidance for navigating care for juvenile idiopathic arthritis
To navigate juvenile idiopathic arthritis effectively, seek a pediatric rheumatologist who specializes in inflammatory joint disorders. They can provide tailored management strategies and monitor disease progression. You can also explore participation in clinical trials, which may offer access to cutting-edge therapies. For additional resources, visit GARD at rarediseases.info.nih.gov for information on rare diseases. Although no patient organizations are currently identified, connecting with other families through online forums may provide support and shared experiences.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.
AI-curated news mentioning juvenile idiopathic arthritis
Updated Feb 2, 2026
The National Institute of Arthritis and Musculoskeletal and Skin Diseases has announced a partially closed meeting. This meeting will discuss ongoing research and initiatives related to arthritis and musculoskeletal diseases.
A new CDC study reveals that arthritis significantly affects African-Americans and Hispanics more than whites, leading to increased pain and limitations. This highlights the need for targeted interventions in these communities.
A CDC study reveals that arthritis can hinder physical activity in individuals with heart disease, potentially complicating their management. This finding highlights the need for integrated care approaches addressing both conditions.
A new CDC study reveals that over 50% of adults with diabetes also suffer from arthritis, which hinders their ability to engage in physical activity crucial for diabetes management. This highlights the need for integrated care strategies addressing both conditions.
The CDC reports that work limitations due to arthritis affect 3.4% of adults in Hawaii and up to 15% in Kentucky, highlighting significant regional disparities. This first-ever state-by-state data underscores the need for targeted interventions in affected areas.